PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study

Key Points

• This research examines how PCSK9 inhibitors affect outcomes in ASCVD patients who have not experienced previous ischaemic events.
• Conducted an observational study
• Analyzed clinical practice data
• Compared outcomes of patients treated with PCSK9 inhibitors against those not receiving the treatment.
• Patients treated with PCSK9 inhibitors had lower ischaemic event rates.
• Mortality rates were also reduced in patients receiving treatment.